Danaher Co. (NYSE:DHR) Shares Sold by Cedar Mountain Advisors LLC

by · The Markets Daily

Cedar Mountain Advisors LLC lessened its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 41.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 117 shares of the conglomerate’s stock after selling 83 shares during the quarter. Cedar Mountain Advisors LLC’s holdings in Danaher were worth $33,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Tsfg LLC raised its position in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. nVerses Capital LLC acquired a new position in Danaher during the second quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher in the first quarter valued at about $30,000. Finally, Richardson Financial Services Inc. purchased a new stake in Danaher during the 4th quarter valued at approximately $42,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.8 %

Shares of Danaher stock traded up $2.08 during trading on Tuesday, reaching $273.64. The company had a trading volume of 752,058 shares, compared to its average volume of 2,712,970. The company has a market cap of $202.68 billion, a price-to-earnings ratio of 46.03, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The firm’s fifty day moving average is $270.36 and its 200-day moving average is $259.43. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the firm earned $2.05 earnings per share. The company’s quarterly revenue was down 2.9% on a year-over-year basis. On average, analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s payout ratio is 18.31%.

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on DHR. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Barclays upped their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Stifel Nicolaus raised their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Bank of America raised their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $282.12.

View Our Latest Stock Report on DHR

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).